Indian Journal of Clinical Biochemistry

, Volume 30, Issue 2, pp 124–133 | Cite as

Reconnoitring the Status of Prostate Specific Antigen and its Role in Women

Review Article
First Online:
Received:
Accepted:

Abstract

Prostate specific antigen is considered to be a tumour marker having maximum utility and specificity for prostate cancer since decades. After the discovery of methods to quantify different molecular fractions of prostate specific antigen (PSA), its usefulness in diagnosing early prostate cancer cases has increased tremendously. The “specificity” of PSA, is now challenged by many studies which proved that PSA, once believed to be secreted exclusively by prostatic epithelium, is also present in females. The exact biological role of extraprostatic PSA is still debatable though many theories substantiated by in vitro evidence has been put forward. With the advent of ultrasensitive analytical techniques, PSA is now quantifiable in female serum in its various molecular forms and this has led to many assumptions of it being useful as a marker in female breast cancers. In a similar scenario to prostate cancer, the ratio of free to total PSA is shown to be useful in detecting early breast cancer cases. It is also shown to be a good prognostic indicator and a predictor of response to therapy and recurrence. Apart from its role in breast cancer, it has been advocated to be a marker of hyper androgenic states in women like hirsutism and polycystic ovarian syndrome. Conflicting reports regarding the role of extra prostatic PSA is accumulating but it has been proven beyond doubt that PSA is no longer specific and confined to prostate gland. Various studies have registered that PSA is an ubiquitous molecule, secreted by hormone responsive organs and its synthesis is stimulated by androgens and progesterone but not oestrogens. In this article, a review of various literatures is done about the presence of extra prostatic PSA, its probable role in those sites as well as its utility as a tumour marker in breast cancer.

Keywords

Prostate specific antigen Tumour marker Breast cancer Fibroadenoma Hyperandrogenism Specificity Sensitivity 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Ablin RJ, Bronson P, Soanes WA, Witebsky E. Tissue- and species-specific antigens of normal human prostatic tissue. J Immunol. 1970;104:1329–39.Google Scholar
  2. 2.
    Hara M, Koyanagi Y, Inoue T, Fukuyama T. Some physicochemical characteristics of gamma-semino protein, an antigenic component specific for human seminal plasma. Jpn J Leg Med. 1971;25:322–4.Google Scholar
  3. 3.
    Li TS, Beling CG. Isolation and characterization of two specific antigens of human seminal plasma. Fertil Steril. 1973;24(2):134–44.PubMedGoogle Scholar
  4. 4.
    Sensabaugh GF. Isolation and characterization of a semen-specific protein from human seminal plasma: a potential new marker for semen identification. J Forensic Sci. 1978;23:106–15.PubMedGoogle Scholar
  5. 5.
    Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol. 1979;17:159–63.PubMedGoogle Scholar
  6. 6.
    Papsidero LD, Wang MC, Valenzuela LA, Murphy GP, Chu TM. A prostate antigen in sera of prostate cancer patients. Cancer Res. 1980;40:2428–32.PubMedGoogle Scholar
  7. 7.
    Stamey TA, Yang N, Hay AR, et al. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317(15):909–16.CrossRefPubMedGoogle Scholar
  8. 8.
    Mikolajczyk SD, Grauer LS, Millar LS, et al. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology. 1997;50:710–4.CrossRefPubMedGoogle Scholar
  9. 9.
    Noldus J, Chen Z, Stamey TA. Isolation and characterization of free form prostate specific antigen (f-PSA) in sera of men with prostate cancer. J Urol. 1997;1(58):1606–9.CrossRefGoogle Scholar
  10. 10.
    Oesterling JE, Martin SK, Bergstralh EJ, et al. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA. 1993;269(1):57–60.CrossRefPubMedGoogle Scholar
  11. 11.
    Williams PB, Eastham JA, Culkin DJ, Mata J, Venable DD, Sartor O. Influence of hepatic function on serum levels of prostate specific antigen. J Urol. 1997;158:1867–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Lilja H, Oldbring J, Rannevik G, Laurell CB. Seminal vesicle secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest. 1993;80:185–281.Google Scholar
  13. 13.
    Iwamura M, Hellman J, Cockett AT, Lilja H, Gershagen S. Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. Urology. 1996;48:317–25.CrossRefPubMedGoogle Scholar
  14. 14.
    Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab. 1992;75:1046–53.PubMedGoogle Scholar
  15. 15.
    Yoshida E, Ohmura S, Sugiki M, Mamyama M, Mihara H. Prostate specific antigen activates single chain urokinase-type plasminogen activator. Int J Cancer. 1995;63:863–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Watt KWK, Lee PJ, M’Timkulu T, Chan WP, Loor R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci. 1986;83:3166–70.CrossRefPubMedCentralPubMedGoogle Scholar
  17. 17.
    Webber MM, Waghray A, Bello D. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res. 1995;1:1089–94.PubMedGoogle Scholar
  18. 18.
    Fortier AH, Nelson BJ, Grella DK, Holaday JW. Antiangiogenic activity of prostate-specific antigen. J Natl Cancer Inst. 1999;91:1635–40.CrossRefPubMedGoogle Scholar
  19. 19.
    Fortier AH, Holaday JW, Liang H, Dey C, Grella DK, Holland-Linn J, Vu H, Plum SM, Nelson BJ. Recombinant prostate-specific antigen inhibits angiogenesis invitro and in vivo. Prostate. 2003;56:212–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Mattsson JM, Laakkonen P, Stenman UH, Koistinen H. Antiangiogenic properties of prostate-specific antigen. Scand J Clin Lab Invest. 2009;69:447–51.CrossRefPubMedGoogle Scholar
  21. 21.
    Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 1991;51(1):222–6.PubMedGoogle Scholar
  22. 22.
    Woodrum DL, Brawer MK, Partin AW, Catalona WJ, Southwick PC. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol. 1998;159:5–12.CrossRefPubMedGoogle Scholar
  23. 23.
    Partin AW, Kelly CA, Subong ENP, Wash PC, Chan DW, Wang TJ, Rittenhouse HG, Wolfert RL, Nortin KC, Cormack MCR. Measurement of the ratio of free PSA to total PSA improves prostate cancer detection for men with total PSA levels between 4 and 10 ng/ml. J Urol. 1995;153:295A.Google Scholar
  24. 24.
    Manello F, Miragoli G, Bianchi G, Gazzanelli G. Prostate specific antigen in ascitic fluid. Clin Chem. 1997;43(8):1461–2.Google Scholar
  25. 25.
    Melegos DN, Yu H, Allen LC, Diamandis EP. Prostate specific antigen in amniotic fluid of normal and abnormal pregnancies. Clin Biochem. 1996;29:555–62.CrossRefPubMedGoogle Scholar
  26. 26.
    Diamandis EP, Yu H. Nonprostatic sources of prostate specific antigen. Urol Clin N Am. 1997;24:275–82.CrossRefGoogle Scholar
  27. 27.
    Bodey B, Bodey B Jr, Kaiser HE. Immunocytochemical detection of prostate specific antigen expression in human primary and metastatic melanomas. Anticancer Res. 1997;17:2343–6.PubMedGoogle Scholar
  28. 28.
    Zarghami N, Levesque M, D’Costa M, Angelopoulou K, Diamandis EP. Frequency of expression of prostate specific antigen mRNA in lung tumours. Am J Clin Pathol. 1997;108(2):184–90.PubMedGoogle Scholar
  29. 29.
    Clements JA, Mukhtar A, Verity K, Pullar M, Mcneil P, Cummins J, Fuller PJ. Kallikreins gene expression in human pituitary tissues. Clin Endocrinol. 1996;44:223–31.CrossRefGoogle Scholar
  30. 30.
    Yamamoto M, Miyake HH. Raised prostate specific antigen in adenocarcinoma of the colon. Int Urol Nephrol. 1997;29:221–5.CrossRefPubMedGoogle Scholar
  31. 31.
    Carder PJ, Speirs V, Ramsdale J, Lansdown MRJ. Expression of prostate specific antigen in male breast cancer. J Clin Pathol. 2005;58:69–71.CrossRefPubMedCentralPubMedGoogle Scholar
  32. 32.
    Miller MK, Unger PD, Bleiweiss IJ. Immunohistochemical analysis of prostate specific antigen in breast cancer. Breast Cancer Res Treat. 2001;68:111–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Kidwai MK, Gong Y, Sun X, et al. Expression of androgen receptor and prostate-specific antigen in male breast carcinoma. Breast Cancer Res. 2004;6:18–23.CrossRefGoogle Scholar
  34. 34.
    Kraus TS, Cohen C, Siddiqui MT. Prostate-specific antigen and hormone receptor expression in male and female breast carcinoma. Diagn Pathol. 2010;5:63.CrossRefPubMedCentralPubMedGoogle Scholar
  35. 35.
    Diamandis EP, Yu H. New biological functions of prostate-specific antigen? J Clin Endocrinol Metab. 1995;80:1515–7.CrossRefPubMedGoogle Scholar
  36. 36.
    Borchert GH, Melegos DN, Tomlinson G, Giai M, Roagna M, Ponzone R, Sgro L, Diamandis EP. Molecular forms of prostate-specific antigen in the serum of women with benign and malignant breast diseases. Br J Cancer. 1997;16:1087–94.CrossRefGoogle Scholar
  37. 37.
    Wernert N, Albrech M, Sesterhenn I, Goebbels R, Bonkhoff H, Seitz G, Inniger R, Remberger K. The ‘female prostate’. Location, morphology, immune histochemical characteristics and significance. Eur Urol. 1992;22:64–9.PubMedGoogle Scholar
  38. 38.
    Clements JA, Mukhtar A. Glandular kallikreins and prostate specific antigen are expressed in the human endometrium. J Clin Endocrinol Metab. 1994;78:1536–9.PubMedGoogle Scholar
  39. 39.
    Zarghami N, Grass L, Sauter ER, Diamandis EP. Prostate specific antigen levels in serum during the menstrual cycle. Clin Chem. 1997;43:1862–7.PubMedGoogle Scholar
  40. 40.
    Melegos DN, Yu H, Ashok M, Wang C, Stanczyk F, Diamandis EP. Prostate-specific antigen in female serum, a potential new marker for androgen excess. J Clin Endo Metab. 1997;82:777–80.CrossRefGoogle Scholar
  41. 41.
    Mannello F, Sebastiani M, Amati S, Gazzanelli G. Prostate specific antigen expression in a case of intracystic carcinoma of the breast: characterization of immune reactive protein and literature surveys. Clin Chem. 1997;43–8:1448–54.Google Scholar
  42. 42.
    Chan DW, Booth AR, Diamandis EP. “Tumour markers”; Tietz text book of clinical chemistry and molecular diagnostics. 4th Edition. 2006; 745–786.Google Scholar
  43. 43.
    Borchert G, Giai M, Diamandis EP. Elevated levels of prostate specific antigen in serum of women with fibroadenomas and breast cysts. J Natl Cancer Inst. 1997;89:587–8.CrossRefPubMedGoogle Scholar
  44. 44.
    Radowicki S, Kunicki M, Bandurska-Stankiewicz E. Prostate-specific antigen in the serum of women with benign breast disease. Eur J Obstet Gynecol Reprod Biol. 2008;138(2):212–6.CrossRefPubMedGoogle Scholar
  45. 45.
    Diamandis EP, Yu H, Lopez-Otin C. Prostate-specific antigen—a new constituent of breast cyst fluid. Breast Cancer Res Treat. 1996;38:259–64.CrossRefPubMedGoogle Scholar
  46. 46.
    Yu H, Diamandis EP, Levesque M, Giai M, Roagna R, Ponzone R, Sismondi P, Monne M, Croce C. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat. 1996;40:171–8.CrossRefPubMedGoogle Scholar
  47. 47.
    Gau JT, Salter RD, Krill D, Grove ML, Becich MJ. The biosynthesis and secretion of prostate-specific antigen in LNCaP cells. Cancer Res. 1997;57:3830–4.PubMedGoogle Scholar
  48. 48.
    Monne M, Croce CM, Yu H, Diamandis EP. Molecular characterization of prostate-specific antigen mRNA expressed in breast tumours. Cancer Res. 1994;54:6344–7.PubMedGoogle Scholar
  49. 49.
    Diamandis EP, Yu H, Sutherland DJA. Detection of prostate-specific antigen immune reactivity in breast tumours. Breast Cancer Res Treat. 1994;32:301–10.CrossRefPubMedGoogle Scholar
  50. 50.
    Ferguson RA, Yu H, Kalyvas M, Zammit S, Diamandis EP. Ultrasensitive detection of prostate-specific antigen by a time resolved immunofluorometric assay and the Immulite® immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clin Chem. 1996;5(42):675–84.Google Scholar
  51. 51.
    Zarghami N, Grass L, Diamandis EP. Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. Br J Cancer. 1997;75:579–88.CrossRefPubMedCentralPubMedGoogle Scholar
  52. 52.
    Hall RE, Clements JA, Birrell SN, Tilley WD. Prostate specific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumours. Br J Cancer. 1998;78:360–5.CrossRefPubMedCentralPubMedGoogle Scholar
  53. 53.
    Yu H, Diamandis EP, Zarghami N, Grass L. Induction of prostate-specific antigen production by steroids and tamoxifen in breast cancer cell lines. Br Cancer Res Treat. 1994;32:291–300.CrossRefGoogle Scholar
  54. 54.
    Nagar R, Sharma KK. Prostate specific antigen in cord blood. Ind J Clin Biochem. 2012;27(4):375–8.CrossRefGoogle Scholar
  55. 55.
    Breul J, Pickl U, Schaff J. Extra prostatic production of prostate specific antigen is under hormonal control. J Urol. 1997;157:212–3.CrossRefPubMedGoogle Scholar
  56. 56.
    Obiezu CV, Giltay EJ, Magklara A, et al. Serum and urinary prostate-specific antigen and urinary human glandular kallikrein concentration are significantly increased after testosterone administration in female-to male transsexuals. Clin Chem. 2000;46:859–62.PubMedGoogle Scholar
  57. 57.
    Bayatti AA, Samak SH, Bahar AJ. Can serum prostate-specific antigen be a promising marker for patients with polycystic ovary syndrome and hirsutism. Middle East Fertil Soc J. 2004;9(3):227–31.Google Scholar
  58. 58.
    Gullu S, Emral R, Asik M, Cesur M, Tonyukuk V. Diagnostic value of prostatic specific antigen in hirsute women. J Endocrinol Invest. 2003;26:202–1998.CrossRefGoogle Scholar
  59. 59.
    Obiezu CV, Scorilas A, Magklara A, Thornton MH, Wanga Y, Stanczyyk FZ, Diamandis EP. Prostate specific antigen and human glandular kallikrein 2 are markedly elevated in urine of patients with polycystic ovary syndrome. J Clin Endocrinal Metab. 2001;4(86):1558–61.CrossRefGoogle Scholar
  60. 60.
    Black MH, Giai M, Ponzone R, Sismondi P, Yu H, Diamandis EP. Serum total and free prostate-specific antigen for breast cancer diagnosis in women. Clin Cancer Res. 2000;6:467–73.PubMedGoogle Scholar
  61. 61.
    Hautmann S, Huland E, Grupp C, Haese A, Huland H. Supersensitive prostate specific antigen (PSA) in serum of women with benign breast disease or breast cancer. Anticancer Res. 2000;20(3B):2151–4.PubMedGoogle Scholar
  62. 62.
    Abdulnabi HM. Expression of free prostatic specific antigen (PSA) in breast mass. Adv Bioresearch. 2011;2(1):153–8.Google Scholar
  63. 63.
    Mashkoor FC, Al-Asadi JN, Al-Naama LM. Serum level of prostate-specific antigen (PSA) in women with breast cancer. Cancer Epidemiol. 2013;37(5):613–8.CrossRefPubMedGoogle Scholar
  64. 64.
    Dash P, Pati S, Mangaraj M, Sahu PK, Mohapatra PC. Serum total PSA and free PSA in breast tumors. Ind J Clin Biochem. 2011;26(2):182–6.CrossRefGoogle Scholar
  65. 65.
    Chang YF, Hung SH, Lee YJ, Chen RC, Su LC, Lai CS, Chou C. Discrimination of breast cancer by measuring prostate-specific antigen levels in women’s serum. Anal Chem. 2011;83(13):5324–8.CrossRefPubMedGoogle Scholar
  66. 66.
    Kaulsay KK. Serum IGF-binding protein-6 and prostate specific antigen in breast cancer. Eur J Endocrinol. 1999;140:164–8.CrossRefPubMedGoogle Scholar
  67. 67.
    Lehrer S, Terk M, Piccoli SP, Song HK, Lavagnini P, Luderer AA. Reverse transcriptase-polymerase chain reaction for prostate-specific antigen may be a prognostic indicator in breast cancer. Br J Cancer. 1996;74(6):871–3.CrossRefPubMedCentralPubMedGoogle Scholar
  68. 68.
    Foekens JA, Diamandis EP, Yu H, Look MP, Gelder MEM, Klijn JGM. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. Br J Cancer. 1999;79(5/6):888–94.CrossRefPubMedCentralPubMedGoogle Scholar
  69. 69.
    Zhao Y, Verselis SJ, Klar N, Sadowsky NL, Kaelin CM, Smith B, Foretova L, Frederick PL. Nipple fluid carcinoembryonic antigen and prostate-specific antigen in cancer-bearing and tumor-free breasts. J Clin Oncol. 2001;19(5):1462–7.PubMedGoogle Scholar
  70. 70.
    Narita D, Cimpean AM, Anghel A, Raica M. Prostate specific antigen value as a marker in breast cancer. Neoplasma. 2006;53(2):161–7.PubMedGoogle Scholar
  71. 71.
    Romppanen J, Keskikuru R, Kataja V, Eskelinen M, Kosma VM, Savolainen K, Uusitupa M, Mononen I. Measurement of prostate-specific antigen in detection of benign or malignant breast disease in women. Br J Cancer. 1999;79(9–10):1583–7.CrossRefPubMedCentralPubMedGoogle Scholar
  72. 72.
    Giai M, Yu H, Roagna R, Ponzone R, Katsaros D, Levesque MA, Diamandis EP. Prostate-specific antigen in serum of women with breast cancer. Br J Cancer. 1995;72:728–31.CrossRefPubMedCentralPubMedGoogle Scholar
  73. 73.
    Killian CS, Corral DA, Kawinski E, Constantine RI. Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-b and a proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Commun. 1993;192:940–7.CrossRefPubMedGoogle Scholar
  74. 74.
    Cohen P, Peehl DM, Graves HCB, Rosenfeld RG. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol. 1994;142:407–15.CrossRefPubMedGoogle Scholar
  75. 75.
    Oh Y, Gucev Z, Ng L, Muller HL, Rosenfeld RG. Antiproliferative actions of insulin-like growth factor binding protein (IGFBP)-3 on human breast cancer cells. Prog Growth Factor Res. 1995;6:503–12.CrossRefPubMedGoogle Scholar
  76. 76.
    Gill ZP, Perks CM, Newcomb PV, Holly JMP. Insulin like growth factor binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF dependent manner. J Biol Chem. 1997;272:25602–7.CrossRefPubMedGoogle Scholar
  77. 77.
    Bharaj B, Scorilas A, Giai M, Diamandis EP. TA repeats polymorphism of the 5 alpha-reductase gene and breast cancer. Cancer Epidemiol Biomarkers Prev. 2000;9(4):387–93.PubMedGoogle Scholar

Copyright information

© Association of Clinical Biochemists of India 2014

Authors and Affiliations

  1. 1.Department of BiochemistryAll India Institute of Medical SciencesBhubaneswar-19India

Personalised recommendations